Ultragenyx Pharmaceutical Inc. (RARE) News

Ultragenyx Pharmaceutical Inc. (RARE): $35.46

0.66 (+1.90%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add RARE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#98 of 356

in industry

Filter RARE News Items

RARE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RARE News Highlights

  • For RARE, its 30 day story count is now at 3.
  • Over the past 18 days, the trend for RARE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about RARE are DRUG and EC.

Latest RARE News From Around the Web

Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)

Evkeeza is a first-in-class medicine approved by Health Canada, the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultrarare, inherited form of high cholesterolTORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza® (evinacumab) in Canada. Evkeeza® was

Yahoo | September 25, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 33,475 restricted stock units of the company’s common stock to 10 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Empl

Yahoo | September 20, 2023

Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ...

Unpacking the Risks and Rewards

Yahoo | September 7, 2023

Ultragenyx to Participate at Investor Conferences in September

Citi BioPharma Conference on September 6 in Boston Morgan Stanley Healthcare Conference on September 12 in New York City NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in a panel discus

Yahoo | August 31, 2023

Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line

The estate of Henrietta Lacks filed a lawsuit in Maryland federal court on Thursday accusing biopharmaceutical company Ultragenyx Pharmaceutical of unlawfully profiting from cells that were taken from Lacks' body without her consent during a medical procedure in 1951. The lawsuit said that Novato, California-based Ultragenyx, which develops treatments for rare genetic diseases, uses the famous "HeLa" line of cells "like a dairy farm treats cows" to mass-produce materials for gene therapy. Lacks' estate reached a confidential settlement in a similar lawsuit against laboratory-equipment maker Thermo Fisher earlier this month.

Yahoo | August 10, 2023

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Ultragenyx Pharmaceutical fair value estimate is US$60.90...

Yahoo | August 8, 2023

Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call

Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call

Yahoo | August 4, 2023

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.

Yahoo | August 4, 2023

Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update

Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million NOVATO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a

Yahoo | August 3, 2023

Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Initial data expected in first half of 2024NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced it has begun dosing the second dose-escalation cohort in its pivotal Phase 1/2/3 Cyprus2+ study following completion of dosing and safety review in the first cohort. The company's investigational AAV9 gene therapy is designed to deliver stable expression of the ATP7B copper transporter following a single intravenous infusion, with the goal of

Yahoo | July 31, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!